Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congressa??
Google+
Facebook
Vkontakte
Odnoklassniki
-
Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B -
Phase 3 clinical study evaluating bepirovirsen as a monotherapy is anticipated to start in the first half of 2023-
GSK to explore potential combination treatments to further reduce the global burden of chronic hepatitis BCARLSBAD, Calif., June 25, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen (formerly IONIS-HBV
Rx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus (CHB).
See also: